Table 3.
Summary of clinical characteristics of Anaplastic pleomorphic xanthoastrocytoma from literature and our institute.
| Variable | Prior studies (n=56) | Our series | Overall | |
|---|---|---|---|---|
| No. of available cases | Value | |||
| Mean age, years | 56 | 29.6 ± 19.6 | 36.7 ± 20.3 | 31.9 ± 20.0 |
| Sex (M/F) | 56 | 29/27 | 11/15 | 40/42 |
| Seizure | 52 | 20 (38.5) | 8 (30.8) | 28 (35.9) |
| Temporal | 56 | 27 (48.2) | 13 (50) | 40 (48.8) |
| Primary/Secondary | 54 | 45/9 | 22/4 | 67/13 |
| Peritumoral edema | 34 | 23 (67.6) | 21 (80.8) | 44 (73.3) |
| Solid/cystic-solid | 35 | 19/16 | 16/10 | 35/26 |
| Enhancement | 33 | 32 (97.0) | 25 (96.2) | 57 (96.6) |
| BRAF | 26 | 14 (53.8) | 6 (40) | 20 (48.8) |
| GTR | 54 | 24 (44.4) | 17 (65.4) | 41 (51.3) |
| RT | 50 | 31 (62) | 22 (84.6) | 53 (69.7) |
| CT | 50 | 23 (46) | 20 (76.9) | 43 (56.6) |
| BRAF inhibitor | 56 | 7 (12.5) | 0 | 7 (8.5) |
| Recurrence | 49 | 35 (71.4) | 7 (26.9) | 42 (46) |
| Death | 49 | 16 (32.7) | 6 (23.1) | 22 (29.3) |
| Mean PFS, months | 34 | 19.5 ± 32.2 | 19.0 ± 21.2 | 19.3 ± 27.8 |
| Mean FU, months | 40 | 31.4 ± 35.3 | 20.5 ± 21.2 | 27.1± 30.8 |